Last reviewed · How we verify
Fluad_MF59-adjuvanted trivalent influenza subunit vaccine — Competitive Intelligence Brief
marketed
Biologic
Live · refreshed every 30 min
Target snapshot
Fluad_MF59-adjuvanted trivalent influenza subunit vaccine (Fluad_MF59-adjuvanted trivalent influenza subunit vaccine) — Novartis Vaccines.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Fluad_MF59-adjuvanted trivalent influenza subunit vaccine TARGET | Fluad_MF59-adjuvanted trivalent influenza subunit vaccine | Novartis Vaccines | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Fluad_MF59-adjuvanted trivalent influenza subunit vaccine CI watch — RSS
- Fluad_MF59-adjuvanted trivalent influenza subunit vaccine CI watch — Atom
- Fluad_MF59-adjuvanted trivalent influenza subunit vaccine CI watch — JSON
- Fluad_MF59-adjuvanted trivalent influenza subunit vaccine alone — RSS
Cite this brief
Drug Landscape (2026). Fluad_MF59-adjuvanted trivalent influenza subunit vaccine — Competitive Intelligence Brief. https://druglandscape.com/ci/fluad-mf59-adjuvanted-trivalent-influenza-subunit-vaccine. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab